Only slightly more than one-third of percutaneous coronary interventions (PCI) among elective patients are considered appropriate, half are of uncertain value, and the remainder are deemed ...
Guidelines based on study showing BRILINTA reduces risk of cardiovascular events over clopidogrel in patients with Acute Coronary Syndrome WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback